Abstract:BackgroundAlthough recent models suggest that the detection of Circulating Tumor Cells (CTC) in epithelial-to-mesenchymal transition (EM CTC) might be related to disease progression in metastatic breast cancer (MBC) patients, current detection methods are not efficient in identifying this subpopulation of cells. Furthermore, the possible association of EM CTC with both clinicopathological features and prognosis of MBC patients has still to be demonstrated. Aims of this study were: first, to optimize a DEPArray-based protocol meant to identify, quantify and sort single, viable EM CTC and, subsequently, to test the association of EM CTC frequency with clinical data.MethodsThis prospective observational study enrolled 56 MBC patients regardless of the line of treatment. Blood samples, depleted of CD45pos leukocytes, were stained with an antibody cocktail recognizing both epithelial and mesenchymal markers. Four CD45neg cell subpopulations were identified: cells expressing only epithelial markers (E CTC), cells co-expressing epithelial and mesenchymal markers (EM CTC), cells expressing only mesenchymal markers (MES) and cells negative for every tested marker (NEG). CTC subpopulations were quantified as both absolute cell count and relative frequency. The association of CTC subpopulations with clinicopathological features, progression free survival (PFS), and overall survival (OS) was explored by Wilcoxon-Mann-Whitney test and Univariate Cox Regression Analysis, respectively.ResultsBy employing the DEPArray-based strategy, we were able to assess the presence of cells pertaining to the above-described classes in every MBC patient. We observed a significant association between specific CD45neg subpopulations and tumor subtypes (e.g. NEG and triple negative), proliferation (NEG and Ki67 expression) and sites of metastatic spread (e.g. E CTC and bone; NEG and brain). Importantly, the fraction of CD45neg cells co-expressing epithelial and mesenchymal markers (EM CTC) was significantly associated with poorer PFS and OS, computed, this latter, both from the diagnosis of a stage IV disease and from the initial CTC assessment.ConclusionThis study suggests the importance of dissecting the heterogeneity of CTC in MBC. Precise characterization of CTC could help in estimating both metastatization pattern and outcome, driving clinical decision-making and surveillance strategies.

Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance

Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis

Epithelial-mesenchymal transition classification of circulating tumor cells in lung and colon cancer patients: potential role in clinical practice.

Epithelial‑mesenchymal Transition Phenotype of Circulating Tumor Cells is Associated with Distant Metastasis in Patients with NSCLC.

Expression And Clinical Relevance Of Epithelial And Mesenchymal Markers In Circulating Tumor Cells From Colorectal Cancer

Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients

Mesenchymal Phenotype of Circulating Tumor Cells is Associated with Distant Metastasis in Breast Cancer Patients.

Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers

Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients

A preliminary study on the association between epithelial-mesenchymal transition and circulating tumor cells in renal cell carcinoma

Detection of Circulating Tumor Cells and Evaluation of Epithelial-Mesenchymal Transition Patterns of Circulating Tumor Cells in Ovarian Cancer

EMT Status of Circulating Breast Cancer Cells and Impact of Fluidic Shear Stress

Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

Clinical significance of circulating tumor cells in breast cancer patients

Epithelial Circulating Tumor Cells with a Heterogeneous Phenotype Are Associated with Metastasis in NSCLC

Prognostic value of epithelial–mesenchymal transition circulating tumor cells in female breast cancer: A meta-analysis

Epithelial–Mesenchymal Transition Status of Circulating Tumor Cells Is Associated With Tumor Relapse in Head and Neck Squamous Cell Carcinoma

Spatial Heterogeneity in Epithelial to Mesenchymal Transition Properties of Circulating Tumor Cells Associated with Distant Recurrence in Pancreatic Cancer Patients

Detection of Epithelial-Mesenchymal Transition Status of Circulating Tumor Cells in Patients with Esophageal Squamous Carcinoma

In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis